Remarkably, inhibition of nuclear TyrRS using pharmacological or genetic approaches suppresses the hallmark phenotypes of CMT in Drosophila, highlighting the importance of nuclear TyrRS variant for CMT neuropathology; however, the involvement of other cellular compartments or molecules mediating the toxicities outside the nucleus cannot be excluded. This evidence concerns the gene YARS1 and Charcot-Marie-Tooth disease.